ReviewInternational journal of molecular sciences2026
Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer treatment with limited effective therapeutic options. While CIA has traditionally been attributed to direct p53-mediated cytotoxicity against rapidly proliferating keratinocytes in hair bulbs, emerging evidence suggests a more complex pathogenesis that involves immune-mediated mechanisms analogous to those in alopecia areata (AA). This review synthesizes current literature and proposes that CIA may be fundamentally driven by the collapse of hair follicle (HF) immune privilege (IP). We explore how chemotherapy-induced DNA damage and psychophysiological stress converge to trigger inflammation, characterized by interferon-γ (IFN-γ)-driven pathways, oxidative stress, and neuroimmune dysregulation. We highlight histopathological, genetic, and clinical overlaps between CIA and AA, particularly regarding the shared involvement of the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signaling pathway. Consequently, Janus kinase (JAK) inhibitors (JAKi) are evaluated as potential therapeutic agents for CIA. However, the application of JAKi in oncologic populations requires scrutiny regarding potential immunosuppression and risks of malignancies. Finally, we discuss the context-dependent roles of cytokines involved in the HF-IP collapse pathway, such as interleukin (IL)-15 and IL-1, in HF homeostasis versus inflammation, and we outline future research directions for targeted and safe therapeutic strategies that mitigate CIA without compromising cancer treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.